Die Wirkung eines Smartphone-gestützten Hybrid-Herzrehabilitationsprogramms bei Patienten mit Herzinsuffizienz. (SHCR-HF)
The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions:
- Is the novel cardiac rehabilitation model feasible for patients with HF?
- Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Hung-Jui Chuang, MD
- Telefonnummer: 67034 00886-2-23123456
- E-Mail: rexintwo@gmail.com
Studienorte
-
-
-
Taipei, Taiwan
- Rekrutierung
- Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
-
Kontakt:
- Hung-Jui Chuang, MD
- Telefonnummer: 67034 00886-2-23123456
- E-Mail: rexintwo@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients with heart failure between the ages of 18 and 80 years old.
- NYHA (New York Heart Association) functional classification of 1 to 3.
- Patients must be in a stable condition and under outpatient follow-up.
Exclusion Criteria:
- Patients who have contraindications for exercise according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription.
- Patients who are unable to complete cardiopulmonary exercise testing.
- Patients who are unable to follow verbal instructions.
- Patients who are unable to walk independently or pedal a stationary bicycle.
- Patients who are unable to use communication app on a smartphone.
- Patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation.
- Patients who do not provide consent to participate in the trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: smartphone-assisted hybrid cardiac rehabilitation (SHCR)
Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months. |
The 12-week case manager-led SHCR program includes:
|
|
Kein Eingriff: Usual care
Participants receive usual care including general education and exercise suggestion. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change of peak oxygen uptake
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
Peak oxygen uptake will be assessed using cardiopulmonary exercise test before intervention, at 12 weeks (post-intervention), and at 6 months. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Change of 6 minute walking test
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
6 minute walking test will be performed before intervention, at 12 weeks (post-intervention), and at 6 months. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Adherence to prescribed exercise
Zeitfenster: 12 weeks(post-intervention)
|
We will evaluate the percentage of completed prescribed exercises at 12 weeks. |
12 weeks(post-intervention)
|
|
Evaluation of Quality of life
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in 36-Item Short Form Survey(SF-36). |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Depression
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in Patient Health Questionnaire (PHQ-9). The PHQ-9 score ranges from 0-27. Higher scores indicate worsen symptoms. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Anxiety
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in Generalized Anxiety Disorder scale (GAD-7). The GAD-7 score ranges 0-21. Higher scores indicate worsen symptoms. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of physical activity
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will assess the change in physical activity using International Physical Activity Questionnaire(IPAQ) Taiwan version. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of grip strength
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The grip strength will be measured using a grip goniometer with the participants seated and the elbow flexed at 90 degrees. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Evaluation of frailty
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The investigators will evaluate the change in the Clinical Frailty Scale, which ranges from 1 to 9. Higher scores represent greater illness. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: Total cholesterol
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The Total cholesterol will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: LDL
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The LDL will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: HDL
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The HDL will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: Triglyceride
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The Triglyceride will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
|
Blood test: NT-proBNP
Zeitfenster: at baseline, 12 weeks(post-intervention), and 6 months.
|
The NT-proBNP will be tested in the laboratory. |
at baseline, 12 weeks(post-intervention), and 6 months.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Hung-Jui Chuang, MD, Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 202302009RINC
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .